ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate — deforolimus, a novel mTOR inhibitor — has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.